Ocular immune privilege: therapeutic opportunities from an experiment of nature
The DOI matches its Crossref record; 124 of the 125 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the vitreous space, there are higher chances of exposure to systemic circulation,15 whereas the subretinal space does not expose AAV to systemic circulation, owing to the blood-retina barrier.9,33”
From Systemic and local immune responses to intraocular AAV vector administration in non-human primates (2022) · cites this paper as [9]
In the citing paper
“Idebenone (Raxone), a synthetic analogue of coenzyme Q10, has been used by practitioners in the European Union albeit with controversial efficacy, because results from a phase 3 study were not statistically different from placebo.11”
In the citing paper
“The eye was historically considered to be an immune privileged site, as a result of several features. These include the blood-retinal barrier formed by tight junctions between endothelial and retinal pigmented epithelium cells as well as in retinal vessels, the lack of anatomically defined lymphatic drainage and an intraocular anti-inflammatory and immunomodulatory micro-environment [43].”
From Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection (2024) · cites this paper as [43]
In the citing paper
“Additionally, there are lower risks of immunogenicity when targeting AAV vectors towards relatively immune-privileged sites, such as the subretinal space and the cochlea [93,94].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [93]
Citations
Cites
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 2,005 · cited 1×
“CD95L, which is expressed constitutively by cells of the eye (and other immune-privileged tissues), is partially responsible for acceptance of orthotopic corneal allografts, and for making the cornea and retinal pigment epithelium immune-privileged tissue”
BackgroundMedawar, P. B. (1948) · PubMed · Cited by 1,109
Immunologically Privileged Sites
Barker, C. F., & Billingham, R. E. (1978) · Advances in Immunology · doi:10.1016/s0065-2776(08)60930-x · Cited by 815
PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2
Carter, L. L., Fouser, L. A., Jussif, J., Fitz, L., Deng, B., Wood, C. R., Collins, M., Honjo, T., Freeman, G. J., & Carreno, B. M. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9 · Cited by 673
Immunobiology of Tissue Transplantation: A Return to the Passenger Leukocyte Concept
Laffery, K. J., Prowse, S. J., Simeonovic, C. J., & Warren, H. S. (1983) · Annual Review of Immunology · doi:10.1146/annurev.iy.01.040183.001043 · Cited by 509
Suda, T., Hashimoto, H., Tanaka, M., Ochi, T., & Nagata, S. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.12.2045 · Cited by 508 · cited 1×
“Attempts to achieve this goal with CD95L have already been made and the results are mixe”
ResultIdentification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor.
Cousins, S. W., McCabe, M. M., Danielpour, D., & Streilein, J. W. (1991) · PubMed · Cited by 477
Self-citationKang, S.-M., Schneider, D. B., Lin, Z., Hanahan, D., Dichek, D. A., Stock, P. G., & Baekkeskov, S. (1997) · Nature Medicine · doi:10.1038/nm0797-738 · Cited by 450 · cited 1×
“First, conventional immune-recognition pathways can be interrupted by providing allografts with healthy corneal epithelium, or factors derived from this tissue that suppress lymphangiogenesis and attendant inflammatio”
BackgroundSo, K.-F., & Aguayo, A. J. (1985) · Brain Research · doi:10.1016/0006-8993(85)91047-9 · Cited by 390
CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.
Stuart, P. M., Griffith, T. S., Usui, N., Pepose, J., Yu, X., & Ferguson, T. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119173 · Cited by 367 · cited 1×
“CD95L, which is expressed constitutively by cells of the eye (and other immune-privileged tissues), is partially responsible for acceptance of orthotopic corneal allografts, and for making the cornea and retinal pigment epithelium immune-privileged tissue”
Background
Research works printed but not linked: 5
- Haskova, Z., Arancibia-Carcamo, C. V., Christianson, G. J., Roopenian, D. C. & Ksander, B. R. in Uveitis in the Third Millenium (eds Dodds, E. M. & Couto, C. A.) 7–10 (Elsevier Science, Amsterdam, 2000).
- Sano, Y., Ksander, B. R. & Streilein, J. W. Fate of orthotopic corneal allografts in eyes that cannot support ACAID induction. Invest. Ophthalmol. Vis. Sci. 36, 2176–2185 (1995). This paper shows how immune privilege in the eye is disrupted by experimental manipulations of the cornea.
- Bora, H. S. et al. in Advances in Ocular Imunolology (eds Nussenblatt, R. B., Whitcup, S. M., Caspi, R. R. & Gery, I.) 83–86 (Amsterdam, Elsevier, 1994).
- Hori, J. & Streilein, J. W. Role of recipient epithelium in promoting survival of orthotopic corneal allografts in mice. Invest. Ophthalmol. Vis. Sci. 42, 720–726 (2001).
- Ishida, K., Panjwani, N., Cao, Z. & Streilein, J. W. Participation of pigment epithelium in ocular immune privilege. 3. Galectin-1 contributes to immunosuppressive properties of retinal pigment epithelium. Ocular Immun. Inflamm. (in the press).
Cited by
Items 101–200 of 806
The role of the gut microbiome in eye diseases
Zysset‐Burri, D. C., Morandi, S. C., Herzog, E. L., Berger, L., & Zinkernagel, M. S. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101117 · Cited by 113
“The intraocular space is considered an immune-privileged site (Streilein, 2003) and the intraocular cavity is considered sterile unless there is an infection.”
BackgroundGraft failure IV. Immunologic mechanisms of corneal transplant rejection
Chong, E.-M., & Dana, M. R. (2007) · International Ophthalmology · doi:10.1007/s10792-007-9099-9 · Cited by 99
“Streilein and others have shown that the cornea and the AC are not ‘‘immunologically ignorant’’, rather, immune quiescence is actively maintained [ 23 ].”
BackgroundHu, S. J., Calippe, B., Lavalette, S., Roubeix, C., Montassar, F., Housset, M., Levy, O., Delarasse, C., Paques, M., Sahel, J.-A., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.3955-14.2015 · Cited by 95
“If the inflammatory M response is not quickly controlled, it can contribute to disease progression, in particular in tissues with low regenerative capacities such as the brain or the eye (Streilein, 2003; Ransohoff, 2009; Conductier et al., 2010).”
BackgroundOcular surface inflammation is regulated by innate immunity
Ueta, M., & Kinoshita, S. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.05.003 · Cited by 102
“On the ocular surface, as in the intestines and airway, the surface epithelium serves a critical function as the front-line defense of the mucosal innate immune system (Haynes et al., 1999; Streilein, 2003).”
New insights into mononuclear phagocyte biology from the visual system
Reyes, N. J., O'Koren, E. G., & Saban, D. R. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.13 · Cited by 93
High-risk corneal allografts and why they lose their immune privilege
Niederkorn, J. Y. (2010) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32833dfa11 · Cited by 93
Cuffy, M. C., Silverio, A. M., Qin, L., Wang, Y., Eid, R., Brandacher, G., Lakkis, F. G., Fuchs, D., Pober, J. S., & Tellides, G. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5246 · Cited by 91
“More recently, the immunoprivileged status of the brain and eye has been ascribed to immune deviation due to a number of factors in the local microenvironment, including neuropeptides, TGF - , and Fas ligand (10, 11).”
BackgroundSonoda, K., Sakamoto, T., Qiao, H., Hisatomi, T., Oshima, T., Tsutsumi‐Miyahara, C., Exley, M., Balk, S. P., Taniguchi, M., & Ishibashi, T. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02239.x · Cited by 87
Biteman, B., Hassan, I. R., Walker, E., Leedom, A. J., Dunn, M., Seta, F., Laniado-Schwartzman, M., & Gronert, K. (2007) · The FASEB Journal · doi:10.1096/fj.06-7918com · Cited by 90
“The challenge of maintaining adequate host defense while actively suppressing inflammatory and immunogenic responses, especially in response to injury, is nowhere as acute and evolutionarily conserved as in the avascular and transparent tissues of the eye, where every inflammatory/reparative response could dramaticall…”
BackgroundEvading the immune response upon in vivo gene therapy with viral vectors.
Sack, B. K., & Herzog, R. W. (2009) · PubMed · Cited by 107
Gene therapy for inherited retinal and optic nerve degenerations
Moore, N. A., Morral, N., Ciulla, T. A., & Bracha, P. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389886 · Cited by 89
“Additional advantages include ease of accessibility for delivery of the genetic material directly to the target cells of interest, the noninvasive ability to monitor for disease progression and response to therapy, and use of the contralateral eye as an in vivo control [15].”
BackgroundSugita, S., Usui, Y., Horie, S., Futagami, Y., Aburatani, H., Okazaki, T., Honjo, T., Takeuchi, M., & Mochizuki, M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2846 · Cited by 89
Ocular Microbiota and Intraocular Inflammation
Li, J. J., Yi, S., & Wei, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609765 · Cited by 107
“in ocular fluids or constitutively expressed by ocular parenchymal cells (55).”
BackgroundOphthalmic Drug Delivery: Development and Regulatory Considerations
Novack, G. D. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.297 · Cited by 87
Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors
Mrass, P., & Weninger, W. (2006) · Immunological Reviews · doi:10.1111/j.1600-065x.2006.00433.x · Cited by 103
“Immune privilege is a state of particular organs, including the brain, eye, and gonads, characterized by an absent or limited response of the immune system to antigenic challenge (1, 2).”
BackgroundVerma, A., Artiushin, S., Matsunaga, J., Haake, D. A., & Timoney, J. F. (2005) · Infection and Immunity · doi:10.1128/iai.73.11.7259-7266.2005 · Cited by 102
“This may be explained by the immunosuppressive and anti-inflammatory effects of transforming growth factor 2 and other factors responsible for ocular immune privilege (13, 44, 45).”
BackgroundConsensus Statement on the Immunohistochemical Detection of Ocular Lymphatic Vessels
Schroedl, F., Kaser-Eichberger, A., Schlereth, S. L., Bock, F., Regenfuss, B., Reitsamer, H. A., Lutty, G. A., Maruyama, K., Chen, L., Lütjen-Drecoll, E., et al. (2014) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.14-15638 · Cited by 81
“sites within the eye including the absence of a ‘‘classical’’ ocular lymphatic system.(2) Recent advances in lymphangiogenesis research,(3) have however, shown that lymphangio-”
BackgroundFoundational concepts in the biology of bacterial keratitis
Ung, L., & Chodosh, J. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108647 · Cited by 90
Corneal xenotransplantation: Where are we standing?
Yoon, C. H., Choi, H. J., & Kim, M. K. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100876 · Cited by 91
Sadaka, A., Durand, M. L., & Gilmore, M. S. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.03.004 · Cited by 82
“…by the concerted actions of immune modulators including TGF-β, Fas ligand, α-MSH and others, thus limiting inflammatory reactions in the eye and preserving clarity of the visual axis during infection elsewhere in the body (Streilein 2003), but potentially leaving the eye vulnerable to infection.”
Immunological aspects of RPE cell transplantation
Sugita, S., Mandai, M., Kamao, H., & Takahashi, M. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100950 · Cited by 77
“For example, it is possible that mouse primary RPE cell cultures may include other retina/choroid cells due to the protocols (Sugita and Streilein, 2003).”
BackgroundVarela, M. D., de Guimarães, T. A. C., Georgiou, M., & Michaelides, M. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-318483 · Cited by 89
Yam, G. H., Riau, A. K., Funderburgh, M. L., Mehta, J. S., & Jhanji, V. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108062 · Cited by 97
Roadmap for Clinical Translation of Mobile Microrobotics
Bozuyuk, U., Wrede, P., Yıldız, E., & Sitti, M. (2024) · Advanced Materials · doi:10.1002/adma.202311462 · Cited by 92
Sugita, S., Futagami, Y., Smith, S. B., Naggar, H., & Mochizuki, M. (2006) · Experimental Eye Research · doi:10.1016/j.exer.2006.08.005 · Cited by 87
Hyaluronan as a promising excipient for ocular drug delivery
Guter, M., & Breunig, M. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.11.035 · Cited by 82
Ito, T., Meyer, K. C., Ito, N., & Paus, R. (2008) · KARGER eBooks · doi:10.1159/000131412 · Cited by 83
Blais, D. R., Vascotto, S. G., Griffith, M., & Altosaar, I. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-0543 · Cited by 74
“The infiltrating polymorphonuclear leukocytes (PMNs) and plasma proteins in the cornea can diffract and obstruct the visual axis, thus causing the focused image to be cast away from the retina.(45) Persistent inflammation may also lead to permanent corneal destruction by scarring, perforation, and blindness.”
BackgroundαB-Crystallin Protects Retinal Tissue during Staphylococcus aureus - Induced Endophthalmitis
Whiston, E., Sugi, N., Kamradt, M. C., Sack, C. S., Heimer, S. R., Engelbert, M., Wawrousek, E. F., Gilmore, M. S., Ksander, B. R., & Gregory, M. S. (2008) · Infection and Immunity · doi:10.1128/iai.01285-07 · Cited by 76
“The eye is an immune-privileged site where inflammation is inhibited to preserve vision by preventing damage to the delicate ocular tissues (34, 41).”
BackgroundInterleukin 35-Producing Exosomes Suppress Neuroinflammation and Autoimmune Uveitis
Kang, M., Choi, J. K., Jittayasothorn, Y., & Egwuagu, C. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01051 · Cited by 72
“Thus, inflammation in the CNS presents unique challenges, as the need to avoid collateral damage that may compromise neuro-retinal or brain functions has to be counterbalanced by the need to eliminate the pathogen (2).”
BackgroundFailed Central Nervous System Regeneration: A Downside of Immune Privilege?
Bechmann, I. (2005) · NeuroMolecular Medicine · doi:10.1385/nmm:7:3:217 · Cited by 84
The Induction of Anterior Chamber-Associated Immune Deviation
Niederkorn, J. Y. (2007) · Chemical Immunology and Allergy · doi:10.1159/000099251 · Cited by 71
Sugita, S., Kamao, H., Iwasaki, Y., Okamoto, S., Hashiguchi, T., Iseki, K., Hayashi, N., Mandai, M., & Takahashi, M. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15619 · Cited by 71
Manifestations of immune tolerance in the human female reproductive tract
Clark, G. F., & Schust, D. J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00026 · Cited by 79
“The pathways that promote immune privilege are best understood in the eye (Streilein, 2003; Niederkorn, 2012).”
BackgroundHow many aqueous humor outflow pathways are there?
Costagliola, C., dell’Omo, R., Agnifili, L., Bartollino, S., Fea, A. M., Uva, M. G., Zeppa, L., & Mastropasqua, L. (2019) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2019.10.002 · Cited by 76
Practical Guidance for Clinical Microbiology Laboratories: Diagnosis of Ocular Infections
Leal, S. M., Rodino, K. G., Fowler, W. C., & Gilligan, P. H. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00070-19 · Cited by 90
Targeting antigen-presenting cells by anti–PD-1 nanoparticles augments antitumor immunity
Ordikhani, F., Uehara, M., Kasinath, V., Dai, L., Eskandari, S. K., Bahmani, B., Yonar, M., Azzi, J. R., Haik, Y., Sage, P. T., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122700 · Cited by 72
“Of note, in addition to immune activation, peripheral tolerance toward antigens (including tumor antigens) can originate in and develop from the spleen (23, 38, 39).”
BackgroundImmune response after central nervous system injury
Salvador, A. F., & Kipnis, J. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101629 · Cited by 78
Sugita, S., Usui, Y., Horie, S., Futagami, Y., Yamada, Y., Ma, J., Kezuka, T., Hamada, H., Usui, T., Mochizuki, M., et al. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2536 · Cited by 75
“We prepared three types of T cells as follows: ( 1 ) anti-CD3 stimulated T cells (control); (2) anti-CD3 stimulated T cells with camptothecin (12 M, positive control); and (3) anti-CD3 stimulated T cells exposed to HCE cells.”
MethodEndogenous LXA4 Circuits Are Determinants of Pathological Angiogenesis in Response to Chronic Injury
Leedom, A. J., Sullivan, A. B., Dong, B., Lau, D., & Gronert, K. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090678 · Cited by 69
“Many insights into the endogenous role of the VEGF network have been gained by using the cornea,(5,6) which maintains an immune-privileged and avascular state despite expression of VEGF-A and its immediate proximity to the vasculature.(7) Specifically, recent findings have demonstrated that avascularity of the cornea…”
BackgroundThe future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67
“The immune privileged status is enabled by the blood-retina barrier formed by tight junctions between endothelial cells and between pigment epithelial cells, by lack of anatomically defined lymphatic drainage and by a range of local anti-inflammatory agents (Streilein, 2003; Dalkara and Sahel, 2014).”
BackgroundTLR2 Mediates the Innate Response of Retinal Muller Glia to Staphylococcus aureus
Shamsuddin, N., & Kumar, A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100565 · Cited by 70
Inducible immune regulation following autoimmune disease in the immune-privileged eye
Kitaichi, N., Namba, K., & Taylor, A. W. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.0204114 · Cited by 65
“The eye is an immunosuppressive microenvironment that uses multiple mechanisms to suppress the activation of T cells that mediate inflammation and cytotoxicity [1].”
BackgroundInfluentialMatching for Human Leukocyte Antigens (HLA) in corneal transplantation – To do or not to do
van Essen, T. H., Roelen, D. L., Williams, K. A., & Jager, M. J. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.01.001 · Cited by 65
“Part of the success of corneal transplantations is based on the immune privilege of the cornea, and hence, corneal grafts have a survival benefit over organ allografts (Niederkorn, 2001; Niederkorn and Stein-Streilein, 2010; Niederkorn, 2006; Skelsey et al., 2001; Streilein, 2003).”
BackgroundInvariant NKT Cells and Tolerance
Nowak, M. A., & Stein‐Streilein, J. (2007) · International Reviews of Immunology · doi:10.1080/08830180601070195 · Cited by 66
“The cooperation between the different cell types involved in nickel tolerance is reminiscent of findings observed in the induction phase of ACAID [30,31].”
BackgroundResultReview of Ocular Immune Privilege in the Year 2010: Modifying the Immune Privilege of the Eye
Hori, J., Vega, J. L., & Masli, S. (2010) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2010.512696 · Cited by 64
Ocular Vascular Diseases: From Retinal Immune Privilege to Inflammation
Wang, X., Wang, T., Lam, E., Álvarez, D., & Sun, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512090 · Cited by 76
“As one of the major ocular c nstituents, aqueous hum r contains various immunomod latory factors, including ne ropeptides, cytokines, growth factors, and soluble cell-surface receptors to suppress inflammation responses and promote the induction of regulatory T cells [20,48,49].”
BackgroundLipoxins in the eye and their role in wound healing
Gronert, K. (2005) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2005.05.009 · Cited by 69
Antibody therapies and their challenges in the treatment of age-related macular degeneration
Volz, C., & Pauly, D. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.02.020 · Cited by 73
Gene therapy for age-related macular degeneration
Moore, N. A., Bracha, P., Hussain, R. M., Morral, N., & Ciulla, T. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356817 · Cited by 63
“Additional advantages include ease of accessibility for delivery of the genetic material directly to the target cells of interest, the noninvasive ability to monitor for disease progression and response to therapy, and use of the contralateral eye as an excellent in vivo control [28].”
BackgroundPluripotent Stem Cells for Retinal Tissue Engineering: Current Status and Future Prospects
Singh, R. K., Cuzzani, O., Binette, F., Sternberg, H., West, M. D., & Nasonkin, I. O. (2018) · Stem Cell Reviews and Reports · doi:10.1007/s12015-018-9802-4 · Cited by 69
Retinal-Cell–Conditioned Medium Prevents TNF-α-Induced Apoptosis of Purified Ganglion Cells
Fuchs, C., Forster, V., Balse, E., Sahel, J., Picaud, S. A., & Tessier, L. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-1177 · Cited by 83
The Maintenance of Lymphatic Vessels in the Cornea Is Dependent on the Presence of Macrophages
Maruyama, K., Nakazawa, T., Cursiefen, C., Maruyama, Y., van Rooijen, N., D'Amore, P. A., & Kinoshita, S. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8010 · Cited by 63
Iris Damage Is Associated With Elevated Cytokine Levels in Aqueous Humor
Aketa, N., Yamaguchi, T., Suzuki, T., Higa, K., Yagi-Yaguchi, Y., Satake, Y., Tsubota, K., & Shimazaki, J. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-21421 · Cited by 64
Epigenetics, microbiota, and intraocular inflammation: New paradigms of immune regulation in the eye
Wen, X., Hu, X., Li, M., Ge, X., Deng, Y., Bible, P. W., & Wei, L. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.01.001 · Cited by 72
“The eye is considered an immune privileged site (Streilein, 2003) with educational gates (Shechter et al.”
Xu, Q., Lee, J., Jankowska−Gan, E., Schultz, J., Roennburg, D. A., Haynes, L. D., Kusaka, S., Sollinger, H. W., Knechtle, S. J., VanBuskirk, A. M., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3983 · Cited by 62
“TE cells (20, 22), yet they can also suppress TE cell-driven delayed-type hypersensitivity (DTH) responses by means of TGF- 1 production (20, 23, 24).”
BackgroundBöhringer, D., Spierings, E., Enczmann, J., Böhringer, S., Sundmacher, R., Goulmy, E., & Reinhard, T. (2006) · Transplantation · doi:10.1097/01.tp.0000235908.54766.44 · Cited by 62
“In animal models, antigen-presenting cells (APC) have been demonstrated to migrate from the graft to the host spleen via the camero-splenic axis (19, 20).”
BackgroundSystemic and local immune responses to intraocular AAV vector administration in non-human primates
Ail, D., Ren, D., Brazhnikova, E., Nouvel-Jaillard, C., Bertin, S., Mirashrafi, S. B., Fisson, S., & Dalkara, D. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.011 · Cited by 61
“In the vitreous space, there are higher chances of exposure to systemic circulation,(15) whereas the subretinal space does not expose AAV to systemic circulation, owing to the blood-retina barrier.(9,33) Hence, intravitreal AAV injections are expected to be more immunogenic than subretinal injections.”
BackgroundEvaluation of an optimized injection system for retinal gene therapy in human patients
Fischer, M. D., Hickey, D. G., Singh, M. S., & MacLaren, R. E. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.086 · Cited by 61
“13,14 Successful sub-retinal gene therapy in the second eye 1.7–3.3 years after treatment of the contralateral eye provides clinical evidence that AAV2 immune responses may be limited.”
InfluentialEmbryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy
Lui, K. O., Waldmann, H., & Fairchild, P. J. (2009) · Current Stem Cell Research & Therapy · doi:10.2174/157488809787169093 · Cited by 63
LRIG1 inhibits STAT3-dependent inflammation to maintain corneal homeostasis
Nakamura, T., Hamuro, J., Takaishi, M., Simmons, S., Maruyama, K., Zaffalon, A., Bentley, A. J., Kawasaki, S., Nagata-Takaoka, M., Fullwood, N. J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci71488 · Cited by 64
“The cornea is a unique transparent epithelial tissue in the body, and nature has found a way to provide the cornea with an antiinflammatory system that greatly reduces the threat of inflammation-induced visual loss (6).”
The immunology of corneal xenotransplantation: a review of the literature
Hara, H., & Cooper, D. K. C. (2010) · Xenotransplantation · doi:10.1111/j.1399-3089.2010.00608.x · Cited by 60
“Antigen placed in the anterior chamber elicits a deviant systemic immune response, termed anterior chamber-associated immune deviation, that includes (i) suppressed delayed hypersensitivity, (ii) preserved humoral immunity, and (iii) primed cytotoxic T-cell responses [47].”
BackgroundLipid Autacoids in Inflammation and Injury Responses: A Matter of Privilege
Gronert, K. (2008) · Molecular Interventions · doi:10.1124/mi.8.1.7 · Cited by 60
Barker, S. E., Broderick, C. A., Robbie, S. J., Duran, Y., Natkunarajah, M., Buch, P., Balaggan, K. S., MacLaren, R. E., Bainbridge, J. W. B., Smith, A. J., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1327 · Cited by 59
“The mechanism of this immune privilege is multifaceted and is the result of several mechanisms, including physical barriers such as the blood–retinal barrier, immunological ignorance and peripheral tolerance of eyederived antigens [20].”
BackgroundCiulla, T. A., Hussain, R. M., Berrocal, A. M., & Nagiel, A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1740676 · Cited by 59
Strategies of pluripotent stem cell-based therapy for retinal degeneration: update and challenges
Maeda, T., Mandai, M., Sugita, S., Kime, C., & Takahashi, M. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.03.001 · Cited by 74
The novel role of lymphatic vessels in the pathogenesis of ocular diseases
Clahsen, T., Hadrian, K., Notara, M., Schlereth, S. L., Howaldt, A., Prokosch, V., Volatier, T. L. A., Hos, D., Schroedl, F., Kaser-Eichberger, A., et al. (2023) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101157 · Cited by 63
Ashour, H. M., & Niederkorn, J. Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8331 · Cited by 59
“A nterior chamber-associated immune deviation (ACAID) 3 is a form of peripheral tolerance that is induced by introducing Ags into the anterior chamber (AC) of the eye and is maintained by Ag-specific regulatory T cells (Tregs) (1, 2).”
BackgroundHori, J. (2008) · Journal of ocular biology, diseases, and informatics · doi:10.1007/s12177-008-9010-6 · Cited by 64
“In response to threats to vision, the eye has soluble and cell surface immunomodulatory factors that act within the oculi to suppress cells and molecules that mediate innate and adaptive immune inflammation [1].”
BackgroundInfluentialAshour, H. M., & Niederkorn, J. Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.5950 · Cited by 60
“unique array of cytokines and cell surface molecules (5, 6).”
BackgroundCamelo, S., Kezic, J. M., Shanley, A. C., Rigby, P. J., & McMenamin, P. G. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1041 · Cited by 59
“Previous studies have shown that most of the Ag injected into the AC is filtered through the spleen.(1,5,6) However, intracamerally injected Ag, intraocular tumor Ag, and Ag derived from corneal allograft also reach the LNs of the head and neck and the mesenteric LNs (MLNs).”
BackgroundLi, G., Lee, C.-Y., Read, A. T., Wang, K., Ha, J., Kuhn, M. N., Navarro, I. D., Cui, J., Young, K., Gorijavolu, R., et al. (2021) · eLife · doi:10.7554/elife.60831 · Cited by 65
“Mechanistic studies evaluating anti-fibrotic activity of ROCKi in the eye are particularly interesting in view of the eye’s immune-privileged status (Streilein 2003), which minimizes the role of macrophages and monocytes as compared to other organ systems.”
BackgroundIndocyanine green angiography in posterior uveitis
Agrawal, R. V., Biswas, J., & Gunasekeran, D. V. (2013) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.112159 · Cited by 58
“Intraocular inflammation is associated with vascular alterations and very often include disturbances of the retinal and/or choroidal circulations.[1,2]”
BackgroundImpaired Recall of CD8 Memory T Cells in Immunologically Privileged Tissue
Dai, Z., Nasr, I. W., Reel, M., Deng, S., Diggs, L., Larsen, C. P., Rothstein, D. M., & Lakkis, F. G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1165 · Cited by 59
“Transplanting allogeneic tissues at immunologically privileged sites has been repeatedly attempted to induce donor-specific immunologic tolerance (1).”
BackgroundHost immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes
Chung, S. H., Mollhoff, I. N., Mishra, A., Sin, T.-N., Ngo, T., Ciulla, T., Sieving, P., Thomasy, S. M., & Yiu, G. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.281 · Cited by 57
“The higher expression in the spleen alludes to a deviant immune response similar to anterior chamber-associated immune deviation—a phenomenon in which immunogen bearing APCs from the eye migrate through the trabecular meshwork to the spleen, where afferent CD4+ Th1 cells and efferent CD8+ cytotoxic T cells differentia…”
BackgroundAL Qtaish, N., Gallego, I., Villate-Beitia, I., Sainz-Ramos, M., López-Méndez, T. B., Grijalvo, S., Eritja, R., Soto-Sánchez, C., Martínez-Navarrete, G., Fernández, E., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030198 · Cited by 57
“This concept needs to be differentiated from the privileged immunity concept, which refers to the capacity of specific organs to select the most suitable and effective immune response to guarantee their proper functions in health and pathology [120].”
BackgroundB7+ Iris Pigment Epithelium Induce CD8+ T Regulatory Cells; Both Suppress CTLA-4+ T Cells
Sugita, S., Ng, T. F., Lucas, P. J., Gress, R. E., & Streilein, J. W. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.118 · Cited by 57
Self-citationMarrone, L., Marchi, P. M., & Azzouz, M. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2012148 · Cited by 56
“Additionally, there are lower risks of immunogenicity when targeting AAV vectors towards relatively immune-privileged sites, such as the subretinal space and the cochlea [93,94].”
BackgroundStargardt macular dystrophy and evolving therapies
Hussain, R. M., Ciulla, T. A., Berrocal, A. M., Gregori, N. Z., Flynn, H. W., & Lam, B. L. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1513486 · Cited by 56
“directly to the target cells of interest, and the non-invasive ability to monitor for disease progression and response to therapy [61].”
BackgroundTherapeutic targeting of STAT pathways in CNS autoimmune diseases
Egwuagu, C. E., & Larkin, J. (2013) · JAK-STAT · doi:10.4161/jkst.24134 · Cited by 54
“e24134-2 JAK-STAT Volume 2 issue 1 eliminate the pathogen.(5) It is now widely accepted that unrestrained neuroinflammatory responses deriving from excessive secretion of cytokines by inflammatory cells contributes to neuronal or photoreceptor cell deficit that precede neurodegenerative changes in uveitis, multiple sc…”
BackgroundProtective role of vitamin D against oxidative stress in diabetic retinopathy
Valle, M. S., Russo, C., & Malaguarnera, L. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3447 · Cited by 63
“cells and sclera fibroblasts as demonstrated by cytoplasmic and nuclear VDR staining.(26) The cytoplasmic expression of CYP27B1 has been observed in ocular barrier cells.”
BackgroundSingle compartment drug delivery
Cima, M. J., Lee, H., Daniel, K. D., Tanenbaum, L. M., Mantzavinou, A., Spencer, K. C., Ong, Q., Sy, J. C., Santini, J. T., Schoellhammer, C. M., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.049 · Cited by 61
“The microenvironment of the eye is designed instead to modulate the cellular and molecular immune response to effectively address various insults, but at the same time suppress the portion of the immune response most responsible for tissue damaging inflammation using built-in mechanisms [146].”
Retinal Pigment Epithelial Cells are a Potential Reservoir for Ebola Virus in the Human Eye
Smith, J. R., Todd, S., Ashander, L. M., Charitou, T., Ma, Y., Yeh, S., Crozier, I., Michael, M., Appukuttan, B., Williams, K. A., et al. (2017) · Translational Vision Science & Technology · doi:10.1167/tvst.6.4.12 · Cited by 57
“Human retinal pigment epithelial cells contribute to ocular immune privilege through the constitutive expression of immunomodulatory molecules, including cytokines and other soluble molecules, and membranebound ligands.(7) The effect of EBOV on the expression of 10 key immunoregulatory molecules by ARPE19 cells was st…”
InfluentialTolerance Induction in Relation to the Eye
Gery, I., & Caspi, R. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02304 · Cited by 57
Diagnosis of systemic metastatic retinal lymphoma
Cao, X., Shen, D., Callanan, D., Mochizuki, M., & Chan, C. (2009) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2009.01797.x · Cited by 53
“In these sites, strong blood–tissue barriers and an altered immune response allow cells, including certain malignant cells expressing nonself antigens, to escape destruction by the immune system (Filippini et al. 2001; Ferguson et al. 2002; Streilein 2003).”
BackgroundMechanisms of Immune Privilege in the Posterior Eye
Stein-Streilein, J. (2013) · International Reviews of Immunology · doi:10.3109/08830185.2012.740535 · Cited by 53
“Immune privilege allows for the eye to be protected by immune responses in the absence of potentially damaging inflammation [1, 2].”
BackgroundGurung, H. R., Carr, M. M., Bryant, K. M., Chucair‐Elliott, A. J., & Carr, D. J. J. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.26 · Cited by 53
Singh, R. K., Occelli, L. M., Binette, F., Petersen‐Jones, S. M., & Nasonkin, I. O. (2019) · Stem Cells and Development · doi:10.1089/scd.2019.0090 · Cited by 54
“Initially, we chose to test a mild immunosuppression regimen (prednisolone only) because the subretinal space is an immune-privileged site [55,114–117], and sustained release of corticosteroids, including prednisolone, has been discussed and noted as a potent suppressor of intraocular inflammation…”
Meng, Z., Chen, Y., Wu, W., Yan, B., Meng, Y., Liang, Y., Yao, X., & Luo, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.841813 · Cited by 56
“Retinal cells are privileged from systemic immune surveillance (6).”
BackgroundInvolvement of B cells in non‐infectious uveitis
Smith, J. R., Stempel, A. J., Bharadwaj, A. S., & Appukuttan, B. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2016.2 · Cited by 55
Role of Thrombospondin-1 in T Cell Response to Ocular Pigment Epithelial Cells
Futagami, Y., Sugita, S., Vega, J., Ishida, K., Takase, H., Maruyama, K., Aburatani, H., & Mochizuki, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6994 · Cited by 52
Romero, M. D., Muino, J. C., Bianco, G. A., Ferrero, M., Juárez, C. P., Luna, J. D., & Rabinovich, G. A. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1234 · Cited by 56
“Some of these mechanisms involve soluble factors found in aqueous humor, which suppress the generation of pathogenic effector T cells and the production of proinflammatory cytokines.(3) In this context, the presence of anti-Gal-1 antibodies recognizing retinal structures may play a potential role in blocking the immun…”
InfluentialA Lesson in Tolerance — Maternal Instruction to Fetal Cells
Burlingham, W. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmcibr0810752 · Cited by 51
Hara, H., Koike, N., Long, C. E., Piluek, J., Roh, D. S., SundarRaj, N., Funderburgh, J. L., Mizuguchi, Y., Isse, K., Phelps, C. J., et al. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6947 · Cited by 51
Ramos, M. F., Baker, J. F. M., Atzpodien, E.-A., Bach, U. C., Brassard, J. A., Cartwright, J., Farman, C. A., Fishman, C. E., Jacobsen, M. C., Junker, U., et al. (2018) · Journal of Toxicologic Pathology · doi:10.1293/tox.31.97s · Cited by 55
“…immunosuppressive factors present in the aqueous collectively promote a microenvironment that spares the visual axis by minimizing inflammation in the anterior chamber that would otherwise cause potential damage to delicate ocular structures (Streilein 2003; Taylor 2009; Taylor and Kaplan 2010).”
BackgroundHoward, O. M. Z., Dong, H., Su, S. B., Caspi, R. R., Chen, X., Plötz, P. H., & Oppenheim, J. J. (2005) · Blood · doi:10.1182/blood-2004-07-2697 · Cited by 50
Kenchegowda, S., Bazan, N. G., & Bazán, H. E. P. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6199 · Cited by 57
Spontaneous Ocular Surface Inflammation and Goblet Cell Disappearance in IκBζ Gene-Disrupted Mice
Ueta, M., Hamuro, J., Yamamoto, M., Kaseda, K., Akira, S., & Kinoshita, S. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-1055 · Cited by 52
Resolution, the grail for healthy ocular inflammation
Gronert, K. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.07.004 · Cited by 55
“…and active suppression of antigen-specific inflammation has been termed anterior chamberassociated immune deviation (ACAID) and extensively studied (Streilein, 1995, 2003; Niederkorn, 2007; Niederkorn and Kaplan, 2007; Stein-Streilein and Taylor, 2007; Niederkorn, 2009; Niederkorn and…”
BackgroundCornea: Window to Ocular Immunology
Niederkorn, J. Y. (2011) · Current Immunology Reviews · doi:10.2174/157339511796196593 · Cited by 56
“The anatomical, physiological, and immunological adaptations that limit immune-mediated inflammation in the eye create the condition known as “immune privilege”, which is believed to be essential for maintaining normal vision [5-8].”
Background
Metadata
- Authors
- Streilein, J. W.
- Affiliations
- Harvard University (US)
- Corresponding author
- Streilein, J. Wayne
- Venue
- Nature Reviews Immunology
- Published
- 2003-11
- Volume
- 3
- Issue
- 11
- Pages
- 879-889
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2166550261
- Cited by
- 807
- References
- 125
- Citations by year
- 2026: 33 · 2025: 33 · 2024: 40 · 2023: 31 · 2022: 43 · 2021: 54 · 2020: 46 · 2019: 31 · 2018: 33 · 2017: 44 · 2016: 39 · 2015: 34 · 2014: 28 · 2013: 31 · 2012: 37
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- ocular immune privilege, eye, intraocular inflammation, vision loss, autoimmune eye disease, corneal transplantation, allograft acceptance, corneal immunology
- MeSH terms
- Animals, Autoimmune Diseases, Eye, Eye Diseases, Humans, Immunity, Inflammation, Transplantation, Homologous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.